Primary analysis
The addition of tiotropium Respimat® 5 μg, 2.5 μg or
1.25 μg to stable medium-dose ICS therapy was associated
with improved lung function: at the end of the
4-week treatment period, statistically significant differences
from placebo Respimat® in adjusted mean peak
FEV1(0-3h) responses were observed for all doses of
tiotropium Respimat® (P < 0.0001 at all doses) (Figure 3).
The largest adjusted mean difference from placebo Respimat®
was observed with tiotropium Respimat® 5 μg
(188 mL, 95% confidence interval: 140, 236)